Provide an overview of a theoretical framework that would support your D.N.P. project.
My PICOT question is: In mental health providers treating patients requiring psychotropic medications (P), does administering the AIMS (Abnormal Involuntary Movement Scale) every visit help to identify patients at risk for tardive dyskinesia with AIMS score over 0 (I), as compared to no current screening (C), reduce the risk of tardive dyskinesia by 25%(O) over four to 6 weeks?
I hope this project will provide the necessary evidence to encourage all psychiatric providers to implement the utilization of AIMS during each visit/ encounter with their patients.
Provide an overview of a theoretical framework that would support your D.N.P. project.
My PICOT question is: In mental health providers treating patients requiring psychotropic medications (P), does administering the AIMS (Abnormal Involuntary Movement Scale) every visit help to identify patients at risk for tardive dyskinesia with AIMS score over 0 (I), as compared to no current screening (C), reduce the risk of tardive dyskinesia by 25%(O) over four to 6 weeks?
I hope this project will provide the necessary evidence to encourage all psychiatric providers to implement the utilization of AIMS during each visit/ encounter with their patients.